First-line targeted therapy for EGFR-mutant lung cancer with TP53 change
Part of Cancer, Lungs & breathing clinical trials.
This Phase 2 study tests two targeted medicines together (aumolertinib plus anlotinib) as first treatment for advanced lung cancer with specific gene changes (EGFR 19del or L858R plus TP53). It aims to see whether the combination is effective and safe when starting treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have advanced (locally advanced or metastatic) non-small cell lung cancer with EGFR 19del or L858R plus a TP53 co-mutation
- You have not started any systemic (whole-body) cancer treatment yet for this lung cancer
- You must be 18–85 years old and able to do normal daily activities (ECOG 0–1)
- You need at least one measurable tumor spot on scans that can be tracked
- Your blood counts and organ tests (bone marrow, liver, kidneys, and clotting) must meet specific minimum ranges
- You must not have certain lung problems like active pneumonia or likely lung scarring (fibrosis) on screening scans
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs (Enrotinib and a paclitaxel antibody) for people with advanced lung cancer that has a specific EGFR mutation and has stopped responding to previous EGFR-targeted therapies. It aims to see if this combination can shrink or slow the cancer.
This trial tests a newer type of EGFR targeted therapy pill for people with advanced non-small cell lung cancer who have not had prior treatment and whose cancer has a specific genetic change called a PACC mutation. The goal is to see if the drug works well for this group.
This trial tests combining two types of cancer drugs—a targeted pill that attacks a specific mutation in your lung cancer cells, followed by an immunotherapy injection when your tumor stops shrinking. The goal is to see if this combination works better than standard treatment alone.
This Phase 1/2 study tests a new drug (RC108) combined with furmonertinib, with or without an immune drug (toripalimab), in people with EGFR-mutated lung cancer that has gotten worse after prior EGFR treatment. It aims to see how safe the treatment is and whether it can shrink tumors or help control the disease.
This trial tests a combination of two targeted drugs (anlotinib and aumolertinib) as the first treatment for advanced lung cancer with a specific EGFR mutation (L858R). The goal is to see if the combination works better than standard care.
This trial tests a new combination of two targeted drugs (HS-20117 and aumolertinib) in people with advanced EGFR-mutant lung cancer who haven't had treatment yet. The goal is to see if the combination works better than current standard treatments.
Hear when a new Anlotinib trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.